Skip to content
Home/Companies/Biotech/Anoat Therapeutics

Anoat Therapeutics

Biotech·France·Active·3yr hold
Entry
2023
Hold
3yr
Status
Active

Who owns Anoat Therapeutics?

Anoat Therapeutics is a French Biotech company, currently owned by AdBio Partners since 2023.

Hand-verified · updated 2026-04-21

Open JSON · CC-BY
AdBio Partners
Investor
AdBio Partners
AFB Fund II · 2021 · VC

Key facts

HQFrance
SectorBiotech

More from AFB Fund II

Other portfolio companies in the same fund.

Orikine Bio
Active
BiotechSpain· 2026
AndzonBio2
AndzonBio2
Active
BiotechFrance· 2025
Cephagenix
Cephagenix
Active
BiotechDenmark· 2025
EvlaBio
Active
BiotechGermany· 2025
AndzonBio1
AndzonBio1
Active
BiotechFrance· 2024
Astraveus
Astraveus
Active
MedTechFrance· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Anoat Therapeutics?

Anoat Therapeutics is currently owned by AdBio Partners, through AFB Fund II, since 2023.

When did AdBio Partners acquire Anoat Therapeutics?

AdBio Partners acquired Anoat Therapeutics in 2023.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue